Evotec establishes spin-off company in the field of nanoparticle-based therapeutics.
M2 EQUITYBITES-March 24, 2016-Evotec establishes spin-off company in the field of nanoparticle-based therapeutics
(C)2016 M2 COMMUNICATIONS http://www.m2.com
Evotec, a drug discovery alliance and development partnership company, has established a spin-off company in the field of nanoparticle-based therapeutics intended to treat immunological disorders.
It was reported yesterday that the new company is called Topas Therapeutics GmbH and it intends to build a range of clinical-stage development projects to treat autoimmune diseases.
The proceeds of the Series A funding are expected to allow Topas to expand and accelerate its proprietary liver-based tolerance induction platform and to progress with its own product development efforts in multiple autoimmune and inflammatory indications, including multiple sclerosis, into clinical proof-of-concept stage.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Mar 24, 2016|
|Previous Article:||Moberg Pharma signs development agreement with Cadila Pharmaceuticals.|
|Next Article:||Artbit app transforms art experience with point-and-snap technology.|